What is mechlorethamine (nitrogen mustard)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

What is Mechlorethamine (Nitrogen Mustard)?

Mechlorethamine (nitrogen mustard) is a topical alkylating chemotherapeutic agent used primarily for the treatment of early-stage mycosis fungoides (MF), a type of cutaneous T-cell lymphoma, available as a 0.02% gel formulation (Ledaga®) approved by the European Medicines Agency. 1

Mechanism of Action

Mechlorethamine functions as an alkylating agent that generates highly reactive aziridinium ions, which bind to DNA and cross-link the two strands, preventing DNA replication and ultimately causing cell death 2, 3. The drug primarily alkylates position N7 of guanine residues in DNA, with monoadducts being the major DNA adducts formed 4, 5. While interstrand cross-links form in lower yields, they are thought to be central to the drug's medicinal activity 4.

Clinical Applications

Primary Indication: Early-Stage Mycosis Fungoides

Mechlorethamine is recommended as a skin-directed therapy for:

  • Stage IA-IIA mycosis fungoides (patches and thin plaques) 6, 1
  • Particularly effective for patients with limited skin involvement

Evidence-Based Efficacy

The largest randomized controlled trial (260 patients) demonstrated:

  • 58% response rate with gel formulation vs. 47% with ointment (measured by CAILS - Composite Assessment of Index Lesion Severity) 1
  • Gel preparation was statistically noninferior to traditional ointment
  • Applied once daily for up to 12 months

Historical retrospective data shows:

  • 51-80% response rates for stage IA disease
  • 26-68% response rates for stage IB disease 1

When combined with betamethasone, a prospective study showed 58% complete response rate with duration of 77 months 1.

Formulations and Administration

Available Preparations

  1. 0.02% gel (Ledaga®) - EMA-approved, provides more practical formulation than historical preparations 1
  2. Historical formulations: aqueous solution or ointment-based preparations 6
  3. 0.04% gel - used in extension studies for patients failing to achieve complete response (26% response rate) 1

Safety Profile

Common Adverse Effects

  • Irritant contact dermatitis: most common side effect, occurring in 10-40% of patients depending on preparation 1
  • The gel formulation may have higher irritant contact reactions compared to aqueous preparations 7

Long-Term Safety

A 30-year population-based cohort study demonstrated:

  • No increased risk of secondary cancers (including nonmelanoma skin cancer or melanoma) 1
  • Mortality and cause-specific mortality were not influenced by mechlorethamine treatment 1

Important Clinical Considerations

When to Use

  • First-line skin-directed therapy for early-stage MF (IA-IIA)
  • Can be used as monotherapy or combined with other treatments like topical steroids
  • Effective for patches and thin plaques but less effective for thicker plaques (where PUVA is preferred) 6

Limitations

  • The gel formulation has a complete response rate of only 13.8%, which represents a decrease in efficacy compared to aqueous-based preparations of similar concentrations 7
  • Not recommended as primary therapy for advanced stages (IIB or higher) 1

Common Pitfall

While the newer gel formulation reduces delayed hypersensitivity reactions, this advantage is offset by higher irritant contact reactions and potentially lower complete response rates compared to traditional aqueous preparations 7. Clinicians should weigh convenience against efficacy when selecting formulation.

References

Related Questions

Provide a summary of the listed HIV‑1 reverse transcriptase, integrase, and protease mutations and assess the appropriateness of Cabenuva (cabotegravir + rilpivirine) for this patient, presented as a chart note.
What can cause Guillain‑Barré syndrome?
Is there a way to continuously monitor an adult patient's temperature while they remain outpatient?
How should I transition a patient from pantoprazole to famotidine?
How should opioid-induced hypotension from morphine and pethidine be managed?
What is the recommended treatment regimen for cellulitis, including antibiotic selection and dosing for patients with and without MRSA risk factors?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.